- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05720260
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
A Randomized, Phase II Study for Premenopausal Metastatic or Locally Advanced Breast Cancer Patients: Capivasertib, Goserelin, Fulvestrant With/Without Durvalumab, Versus Goserelin, Fulvestrant, and Durvalumab, Versus Goserelin/ Fulvestrant.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Yen-Shen Lu, MD, PhD
- Phone Number: 67009 +886-2-23123456
- Email: yslu@ntu.edu.tw
Study Locations
-
-
-
Taipei City, Taiwan, 100
- Recruiting
- Department of Oncology, National Taiwan University Hospital
-
Sub-Investigator:
- Chih-Hung Lin, MD, PhD
-
Contact:
- Yen-Shen Lu, MD, PhD
- Phone Number: 67009 886-2-23123456
- Email: yslu@ntu.edu.tw
-
Principal Investigator:
- Yen-Shen Lu, MD, PhD
-
Sub-Investigator:
- Dwan-Ying Chang, MD
-
Sub-Investigator:
- Tom Wei-Wu Chen, MD, PhD
-
Sub-Investigator:
- I-Chun Chen, MD, PhD
-
Sub-Investigator:
- Wei-Li Ma, MD
-
Sub-Investigator:
- Ming-Yang Wang, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- A histological confirmed ER positive (>1%) invasive breast cancer.
- Locally advanced or metastatic disease with at least one measurable target lesion
- Patients who had not received chemotherapy for locally advanced or metastatic disease
- Patients have to be (i) either primary resistant to hormonal therapy defined as recurrence developed within 2 years of adjuvant hormonal therapy (ii) or resistant to prior hormonal therapy (failed less than 2 lines of hormonal therapy for locally advanced or metastatic breast cancer)
- Patients must be premenopausal or perimenopausal women according the clinical menstrual history or E2 / FSH level based on local hospital guidance. Patient with menopausal status cannot be determined due to ongoing LHRH agonist treatment is allowed if evidence of premenopausal status prior to patients' LHRH agonist usage can be provided and patient is currently aged under or equal to 50.
- ECOG 0-1
- Patients must have adequate organ and marrow reserve measured within 14 days prior to randomization ge older than 20-year-old.
9. All women of childbearing potential must have a negative pregnancy test obtained within 7 days before starting therapy. Patients must not be breastfeeding.
10. Patients with reproductive potential must use effective contraception (hormone or barrier method of birth control) prior to study entry, for the duration of study participation, and for 6 months after the completion of therapy.
11. Patients (or a surrogate) must be able to comply with study procedures and to give signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the clinical study protocol (CSP). The patients (or a surrogate) must be able to provide of signed and dated written ICF prior to any mandatory study specific procedures, sampling, and analyses.
12. Body weight >30 kg 13. Must have a life expectancy of at least 12 weeks
Exclusion Criteria:
- Prior therapy with capivasertib, fulvestrant, anti-PD1 or anti-PDL1 immunotherapy
- Prior chemotherapy for locally advanced or metastatic breast cancer.
- Radiotherapy with a wide field of radiation within 4 weeks before the first dose of study treatment
- The tumor is HER-2 positive by IHC 3+ or IHC 2+/ISH positive.
- Patients must not have active brain metastases or spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring steroids for at least 4 weeks prior to start of study treatment
- Other malignancy within 5 years except cured basal cell or squamous cell skin cancer or carcinoma in situ of the cervix.
- Psychiatric illness or social situation that would preclude study compliance.
- Serious non-healing wound, ulcer, or bone fracture.
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment.
- Prior minor surgery or needle biopsies within 7 days.
- History of allergic reaction to compounds of similar chemical composition to the study drugs.
- Pregnancy or lactation.
- With the exception of alopecia, any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment
- Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
- Known to have tested positive for human immunodeficiency virus
- History of allogenic organ transplantation.
- Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion: a) Patients with vitiligo or alopecia; b) Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; c)Any chronic skin condition that does not require systemic therapy; d) Patients without active disease in the last 5 years may be included but only after consultation with the study physician; e)Patients with celiac disease controlled by diet alone.
- Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent. Refractory nausea and vomiting, malabsorption syndrome, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection, or other condition that would preclude adequate absorption of capivasertib.
- History of another primary malignancy except for: a) Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP and of low potential risk for recurrence; b) Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; c)Adequately treated carcinoma in situ without evidence of disease
- History of leptomeningeal carcinomatosis.
- Previous allogeneic bone marrow transplant or solid organ transplant.
Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:
- Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)
- Systemic corticosteroids at physiologic doses not to exceed <<10 mg/day>> of prednisone or its equivalent
- Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
- Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP.
Any of the following cardiac criteria at screening:
- Mean resting corrected QT interval (QTc) >470 msec obtained from 3 consecutive ECGs
- Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (eg, complete left bundle branch block, third degree heart block)
- Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, potential for Torsades de Pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval
- Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure New York Heart Association (NYHA) grade ≥2
- Uncontrolled hypotension - SBP <90 mmHg and/or DBP <50 mmHg
- Cardiac ejection fraction outside institutional range of normal or <50% (whichever is higher) as measured by echocardiogram.
Clinically significant abnormalities of glucose metabolism as defined by any of the following at screening:
- Patients with diabetes mellitus type I or diabetes mellitus type II requiring insulin treatment
- HbA1c ≥8.0% (63.9 mmol/mol)
- Any investigational agents or study drugs from a previous clinical study within 30 days of the first dose of study treatment
- Potent inhibitors or inducers of CYP3A4 within 2 weeks prior to the first dose of study treatment (3 weeks for St John's wort), or sensitive substrates of CYP344, CYP2C9 and/or CYP2D6 with a narrow therapeutic window within 1 week prior to the first dose of study treatment.
- Participation in another clinical study with an investigational medicinal product (IMP) administered in the last 30 days or 5 half-lives, whichever is longer
- History of hypersensitivity to active or inactive excipients of capivasertib, fulvestrant, durvalumab, goserelin or drugs with a similar chemical structure or class to the above-mentioned drugs
- Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: goserelin/ fulvestrant
Control arm
|
Hormone therapy
Other Names:
Hormone therapy
Other Names:
|
Experimental: goserelin/ fulvestrant/ capivasertib
Control arm plus AKT inhibitor
|
Hormone therapy
Other Names:
Hormone therapy
Other Names:
AKT inhibitor
Other Names:
|
Experimental: goserelin/ fulvestrant/ capivasertib/ durvalumab
Control arm plus AKT inhibitor and immunotherapy
|
Hormone therapy
Other Names:
Hormone therapy
Other Names:
AKT inhibitor
Other Names:
immunotherapy
Other Names:
|
Experimental: goserelin/ fulvestrant/ durvalumab
Control arm plus immunotherapy
|
Hormone therapy
Other Names:
Hormone therapy
Other Names:
immunotherapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival
Time Frame: From time of randomization to death or tumor progression whichever comes first in 200 months
|
PFS comparison between Arm 1 and Arm 2/3/4
|
From time of randomization to death or tumor progression whichever comes first in 200 months
|
Collaborators and Investigators
Investigators
- Study Chair: Yen-Shen Lu, MD, PhD, NTUH
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Immunological
- Hormone Antagonists
- Estrogen Antagonists
- Estrogen Receptor Antagonists
- Fulvestrant
- Goserelin
- Durvalumab
Other Study ID Numbers
- 202109031MIPD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisDaiichi SankyoRecruitingAdvanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast CarcinomaFrance
Clinical Trials on Goserelin
-
CMX ResearchPeptigroupe Inc.CompletedProstate CancerCanada, Georgia
-
Xiangyun ZongZhejiang Cancer HospitalCompletedBreast CancerChina
-
Tampere UniversityFinnish Prostate Cancer GroupUnknownPatients With T1-4 Advanced Prostate CancerFinland
-
Peking University People's HospitalUnknownInfertility Associated With Endometriosis
-
Eurofarma Laboratorios S.A.Recruiting
-
AstraZenecaCompletedAdvanced Breast CancerRussian Federation, Ukraine, Czech Republic
-
Seattle Institute for Biomedical and Clinical ResearchUnited States Department of Defense; University of WashingtonActive, not recruitingMetastatic Prostate Cancer | Androgen Deprivation TherapyUnited States
-
AstraZenecaCompleted
-
AstraZenecaWithdrawn
-
Peking University People's HospitalRecruiting